stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) EV/FCF
As of 6 November 2026, Fortrea Holdings Inc. (FTRE) trades at a EV/FCF of 17.2×. Over the past ten years it has ranged from −207× (December 2025) to 202× (June 2023); the current reading is higher than 61% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 27.8× | 146.78% |
| FY2024 | 11.2× | (66.18%) |
| FY2023 | 33.3× | (80.58%) |
| FY2022 | 171× | 0.00% |
| FY2021 | 171× | 0.00% |
| FY2020 | 171× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 16.0× | 25.23% |
| Jun 2026 | 12.8× | 36.37% |
| Mar 2026 | 9.4× | (66.18%) |
| Dec 2025 | 27.8× | — |
| 13 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| ZYME Zymeworks Inc. compare | −15.5× |
| TRAX First Tracks Biotherapeutics, Inc. compare | −13.8× |
| VIR Vir Biotechnology, Inc. compare | −11.3× |
| REPL Replimune Group, Inc. compare | −8.5× |
| IMNM Immunome, Inc. compare | −7.3× |
| BHVN Biohaven Ltd. compare | −4.6× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 4.6× |
| SRPT Sarepta Therapeutics, Inc. compare | 10.9× |
| FTRE Fortrea Holdings Inc. | 17.2× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))